Interview with Bingshen Li, CEO, SinoGenoMax
SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation…
Address: No. 3-707 North Yongchang Road,BDA,Beijing 100176,P.R.China.,China
Tel: +86 10 6788 3332
Web: http://www.sinogenomax.com/en
As one of the largest genomics-based biotech companies in China, SinoGenoMax Co.,Ltd. was incorporated in September 1998 by a joint investment from the Beijing Municipal Science & Technology Commission and Beijing Boda Sci-Tech Venture Capital Ltd. Its founding members include the Chinese Academy of Medical Sciences, Peking University, the Chinese Academy of Science, and the Beijing Institute of Medical Sciences. The affililated institute, Chinese National Human Genome Center of Beijing (CHGB) was established in October 1998 at SinoGenoMax.
SinoGenoMax participated in the International Human Genome Sequencing Project, and has been closely involved in several major genome-related research projects such as pathogenic microorganism sequencing projects, Chinese population single nucleotide polymorphism (SNP) genotyping project, and other disease genome research projects.
Originally focused on DNA sequencing and analysis, SinoGenoMax has subsequently expanded its expertise in all aspects of molecular biology and protein biology. SinoGenoMax has built up several independent technical groups including genomics group, proteomics group, and molecular biology group. In particular, SinoGenoMax has perfected a rigorous quality-management system to implement process monitoring and quality control for all the procedures we perform. SinoGenoMax has passed the ISO 9001:2000 international certification of quality management system since 2004, and is now preparing to obtain ISO/IEC 17025:2005 accreditation of testing laboratory.
There are currently 100 employees working at SinoGenoMax located in Beijing Economic-Technological Development Area. SinoGenoMax’s 5,000 square meter laboratory building is fully equipped with top class facilities including DNA Sequencers, mass spectrometry, HPLC, Microarray Chip Reader, and lab automation workstation, for high throughput operation and analysis in genomics and proteomics research. A proprietary Laboratory Information Management System(LIMS) has been implemented for standardized management of samples,data and work flow, and all procedures are performed under the guidance of corresponding SOPs.
In the past few years, SinoGenoMax has successfully provided high quality and cost-effective services for several international pharmaceutical companies. Whether in the scientific research or industrial of production, the widely recognized achievements have enabled SinoGenoMax to become the best biotechnology service company at home and abroad.
Large-scale DNA sequencing, Bioinformatics, Protein expression & Purification, Protein Seperation & Identification, Antibody Production, Functional Genomics & Drug Disc. Platform, Genome-Based Target Validation, Pathway-Based Target Validation, siRNA-Based Drug Screening
SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation…
Simon, you established Glory Medical back in 1998. What was the main rationale behind this significant decision? “We already have operations in Sri Lanka and Pakistan, and are exploring projects…
Dr. Chen Hao is the CEO and founder of the promising startup Imsight, the only company focusing on medical imaging analysis using Artificial Intelligence technology in the Greater Bay Area.…
Alex Wang Yimin, founder and CEO of SONTU Medical Imaging, shares the exciting story of SONTU’s development since 2009, their significant investment into R&D and various international certifications like the…
Dr. Lu Xianping is the founder and now Chairman and CEO of one of China’s few truly innovative biotech companies, ChipScreen BioSciences Co. In this exciting interview, he shares the…
Scott Liang, president of Apex (Guangzhou) Tools and Orthopedics discusses the company’s strong positioning on the Chinese medtech market, current strategic priorities, and what differentiates Apex from its competitors. As…
Dami Qiu, founder and CEO of EMP, shares her personal story of how she decided to establish EMP two decades ago, the market opportunities in ultrasound medical equipment in China,…
In this unique interview, Dr. David Peng, CEO of Medical Excellence International (China), shares the company´s foundations, its key milestones as well as its two unique membership programs. He further…
Sheng Sitong, founder and CEO of gene sequencing device company, Considerin Group (formerly HYK Gene), discusses Considerin’s rapid expansion and the development of precision medicine in China. Mr. Sheng, could…
Yuan Qing, President of the Shenzhen Life Science and Biotechnology Association, shares his insights on the characteristics of the life sciences environment in Shenzhen, the importance of the sectors as…
Guangdong province and neighbouring Hong Kong have long been fundamental to China’s metamorphosis into an economic superpower. Notable as one of the country’s most open and dynamic regions, the Pearl…
One of the more eye-catching and ambitious initiatives to come out of last March’s National People’s Congress, Premier Li Keqiang’s grand vision for the cultivation of a globally competitive cluster…
One of China’s biggest vaccine manufacturers was found to have falsified rabies vaccine records causing nationwide parenting chaos. Executives from China’s second largest pharmaceutical company, ChangSheng biotechnology (Changsheng literally translates…
See our Cookie Privacy Policy Here
